AH異動 | 康希諾生物港股漲超8%,科創板漲超11%,墨西哥將購買3500萬劑疫苗
uSMART盈立智投12月10日消息,康希諾生物AH股午後雙雙大漲,截至14:45分,港股漲超8%,科創板漲超11%,此前消息稱墨西哥將購買3500萬劑疫苗。
據媒體報道,墨西哥外交大臣埃塞拉德9日表示,該國衛生部已簽署一項協議,同意購買3500萬劑中國康希諾生物生產的疫苗。埃塞拉德已在社交媒體上宣佈這一消息,並表示墨西哥將在本週內達成交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.